Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: aliveinsf who wrote (312)	7/28/1998 3:31:00 PM
From: Jeffrey Silver	Read Replies (1) \| Respond to of 410

I own Genzyme and think it is a good value. I think that everybody should realize that some of Genzyme's general's earnings come from the fact that they get all of the tax loss credits from the losses of its sister company's even though it records only part of the losses if any. I think about 30% of its EPS comes from this last year even though General's share in the losses where much less.General makes sure when they accumilate enough GENZL stock that they distribute it to shareholders. This keeps the game working.If GENZL ever has income this game would stop.I think that it is in General's interest to keep GENZL at a loss.This year the percent of net income from this relationship will be less and as net income grows maybe it won't matter any more. Does anybody have an opinion on this? Jeffrey

To: aliveinsf who wrote (312)	7/28/1998 5:38:00 PM
From: Caveat Emptor	Read Replies (1) \| Respond to of 410

What is the status of ATRAGEN? What are the projections for when this product will be profitable, or even be approved? Genzyme dumped 4.5 million into it in 1993, and it doesn't seem to be mentioned much. (Genzyme) also took a ton a ARONEX Stock in exchange for the equity investment into the collaboration agreeement. By the way, ARONEX has not traded much lately, and is close to $2.00 a share... almost off the NASDAQ board. As I mentioned in a previous post, Geoffrey Cox was transferred over there to run that company, but in his first year, millions of dollars richer because of Genzyme Stock Sales in 1997, he has not made much of a difference.... Is this product another management misfire, or is there something there? CAVEAT EMPTOR